Each of these companies possesses solid fundamentals and trades at reasonable valuations.
Compare GSK Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: GlaxoSmithKline
GlaxoSmithKline has been one of the few bright spots in the volatile biopharmaceutical space this year.
And perhaps even more in share price appreciation.
But those wins probably won't be all that big.
There's plenty to like with this big pharma stock -- but a few problem spots, too.
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.
An activist investor seems to be pushing for one.
These are two cheap stocks in an overvalued market.
Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over.
These two high-dividend stocks might be great additions to your portfolio.